Allergy · 2023
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hellings Peter W, Alobid Isam, Anselmo-Lima Wilma T, Bernal-Sprekelsen Manuel, Bjermer Leif, Caulley Lisa, Chaker Adam, Constantinidis Jannis, Conti Diego M, De Corso Eugenio, Desrosiers Martin, Diamant Zuzana, Gevaert Philippe, Han Joseph K, Heffler Enrico, Hopkins Claire, Landis Basile N, Lourenco Olga, Lund Valerie, Luong Amber U, Mullol Joaquim, Peters Anju, Philpott Carl, Reitsma Sietze, Ryan Dermot, Scadding Glenis, Senior Brent, Tomazic Peter Valentin, Toskala Elina, Van Zele Thibaut, Viskens An-Sofie, Wagenmann Martin, Fokkens W J
Аннотация
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.